.png){kind=icon}
.png){kind=icon}
Return
SOHO State of the Art Updates and Next Questions | Beyond Romidepsin: Novel Therapeutic Targets and Emerging Strategies for Relapsed and Refractory Peripheral T-Cell Lymphoma
.png){kind=icon}
PRE
AI
I
J
DOI：10.1016/j.clml.2026.06.003.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Peripheral T-cell lymphomas (PTCLs) represent heterogeneous aggressive non-Hodgkin lymphomas with dismal outcomes in the relapsed/refractory (R/R) setting. Following romidepsin's withdrawal from the R/R PTCL indication in 2021, the only FDA approved agents are belinostat, pralatrexate, with modest overall response rates (ORRs) of 25-29%and brentuximab vedotin with an ORR of 87% in RR Anaplastic Large cell lymphoma (ALCL) but lower response rates in other CD30+ subtypes. Median overall survival following relapse is approximately 5.8 months, highlighting urgent need for effective therapies.
Journal
IF:
2.7
Papers:
427
Citations:
4.2K